Jubilant Therapeutics Inc. to Present Data on Isoform Selective PAD4 inhibitors in the Treatment of Cancer at the American Association of Cancer Research Annual (AACR) Meeting 2022
- Thursday, March 10, 2022, 8:43
- Finance
- Add a comment
BEDMINSTER, N.J., March 10, 2022 /PRNewswire/ — Jubilant Therapeutics Inc. (‘Jubilant’), a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, announced today that it will present data on inhibitors…
About the Author
adminasapcorp has written 41816 stories on this site.